PRECOS and Argenta Extend Collaboration to Offer World Class Integrated Oncology Drug Discovery Services
News Mar 23, 2011
Preclinical Oncology Services Limited, has extended its alliance with Argenta to continue providing comprehensive oncology-focussed drug discovery services.
Argenta, a service division of Galapagos NV, provides fully integrated drug discovery services to a range of leading pharmaceutical and biotechnology companies worldwide. The five-year extension of the alliance will allow both companies to offer unrivalled expertise in cancer research to their pharmaceutical clients.
As a world leader in the provision of pre-clinical research services for oncology drug discovery, PRECOS offers unique advanced patient-relevant in vivo models which closely reflect the clinical situation for each aspect of cancer progression, encompassing pre-cancerous lesions, primary tumours and metastasis. This ability to create cell lines from patient primary tissues that "never see plastic" means that cell lines are not selected based on their ability to survive in vitro, but on their true characteristics as cancer cells.
Argenta can now incorporate PRECOS' specialist in vitro, ex vivo and in vivo cancer models and exceptional scientific expertise into its integrated oncology drug discovery service offering, from hit identification through lead optimization and in vivo "proof-of-concept" to clinical candidate selection. The breadth and depth of the two companies' combined capabilities and expertise in oncology research are unique to the industry.
"Argenta has an excellent reputation for providing first class contract drug discovery services to the global pharmaceutical industry; especially in oncology," comments Professor Sue Watson, Chief Scientific Officer, PRECOS. "We are looking forward to working with Argenta across a number of ongoing cancer-focussed contract research programmes, in addition to various major projects currently in the pipeline. This agreement further demonstrates our business growth and commitment to providing innovative drug discovery services."
Dr. John Montana, Managing Director of Argenta added, "PRECOS is a world leader in oncology preclinical research services. Through this alliance our pharmaceutical clients are able to benefit from seamless access to PRECOS' models and scientists. We are excited to have PRECOS as a key extension of our team, working in partnership with our experienced oncology drug discovery scientists."
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE
Policies, economic systems, and marketing practices that promote the consumption of energy-dense, nutrient-poor food, changing behavioral patterns that couple high total energy intake with insufficient physical activity, and human-built environments that amplify these factors are driving a worldwide rise in excess body weight, according to a new report.READ MORE
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019